×

Sign In

Search
Home

Immunovant’s muscle disorder treatment meets main goal in late-stage trial

By Thomson Reuters Mar 19, 2025 | 6:58 AM

(Reuters) -Immunovant said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial.

(Reporting by Christy Santhosh in Bengaluru; Editing by Maju Samuel)

White House considering Burgess to lead CDC, sources say

Trump says US to sign minerals deal with Ukraine shortly

US judge blocks Elon Musk's DOGE from accessing Social Security records

Nike posts smaller drop in quarterly revenue on holiday demand, new launches

FedEx cuts full-year revenue forecast as it struggles to replace USPS contract loss

Southwest flight cancels takeoff after crew mistook Orlando taxiway for runway

Privacy Policy
Terms Of Service

Midwest Communications, Inc.

Copyright © 2025. All Rights Reserved.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.